Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2024, Quick Ratio deteriorated to 0.24 a new company low.

Within Biotechnology & Pharmaceuticals industry 159 other companies have achieved higher Quick Ratio than Genetic Technologies Limited in fourth quarter 2024. While Quick Ratio total ranking in the fourth quarter 2024 has deteriorated compared to the prior quarter from to 3357.

Explain Quick Ratio?
How much Cash & cash equivalents GENE�s has?
What are GENE�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GENE Quick Ratio	(Jun 30 2024) Q4	0 Q3	0 Q2	0 Q1	(Jun 30 2023) Q4
Y / Y Current Liabilities Change	26.94 %	-2.76 %	59.4 %	51.4 %	109.48 %
Y / Y Cash & cash equivalent Change	-86.97 %	-80.15 %	-87.4 %	-89.59 %	-66.61 %
Quick Ratio MRQ	0.24	0.24	0.24	0.24	2.37
GENE's Total Ranking	# 3357	#	#	#	#
Seq. Current Liabilities Change	0 %	-33.23 %	0 %	90.12 %	-23.39 %
Seq. Cash & cash equivalent Change	0 %	-33.23 %	0 %	-80.49 %	52.37 %

Quick Ratio fourth quarter 2024 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 160
Healthcare Sector	# 888
Overall Market	# 3357

Quick Ratio Statistics
High	Average	Low
3.78	1.82	0.24
(Jun 30 2018)		(Jun 30 2024)

Financial Statements
Genetic Technologies Limited's Current Liabilities	$ 3 Millions	Visit GENE's Balance sheet
Genetic Technologies Limited's Cash & cash equivalent	$ 1 Millions	Visit GENE's Balance sheet
Source of GENE's Sales		Visit GENE's Sales by Geography

Cumulative Genetic Technologies Limited's Quick Ratio

GENE's Quick Ratio for the trailling 12 Months

GENE Quick Ratio	(Jun 30 2024) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Jun 30 2023) 12 Months
Y / Y Current Liabilities TTM Growth	33.39 %	43.5 %	81.65 %	108.73 %	136.8 %
Y / Y Cash & cash equivalent TTM Growth	-87.19 %	-78.51 %	-75.32 %	-52.45 %	-10.62 %
Quick Ratio TTM	0.24	0.59	0.79	1.49	2.53
Total Ranking TTM	# 3498	#	#	#	#
Seq. Current Liabilities TTM Growth	4.44 %	-0.59 %	13.12 %	13.58 %	12.35 %
Seq. Cash & cash equivalent TTM Growth	-57.2 %	-25.7 %	-39.81 %	-33.06 %	-28.2 %

Quick ratio ranking by company, industry and sector >> Back to GENE Financial Strength Comparisons >> Go to Compare GENE Quick Ratio to its Competitors

On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q4 2024 to $2.80 millions, cumulative Quick Ratio decreased to 0.24 below the Genetic Technologies Limited average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 154 other companies have achieved higher Quick Ratio than Genetic Technologies Limited. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2024 from to 3498.

Explain Quick Ratio?
How much Cash & cash equivalents GENE�s has?
What are GENE�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 155
Healthcare Sector	# 948
Within the Market	# 3498

trailing twelve months Quick Ratio Statistics
High	Average	Low
3.78	2.8	1.43
(Jun 30 2018)		(Jun 30 2019)

Companies with similar Quick Ratio in the quarter ending Jun 30 2024, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jun 30 2024 MRQ Cash & cash equivalent	Jun 30 2024 MRQ Current Liabilities
Mesoblast Limited	0.67	$ 38.029 Millions	$ 56.932 Millions
Tracon Pharmaceuticals Inc	0.63	$ 6.270 Millions	$ 9.891 Millions
Elutia Inc	0.53	$ 18.188 Millions	$ 34.610 Millions
Bluebird Bio Inc	0.48	$ 144.067 Millions	$ 297.930 Millions
Brainstorm Cell Therapeutics inc	0.45	$ 3.469 Millions	$ 7.691 Millions
Ladrx Corporation	0.45	$ 0.817 Millions	$ 1.828 Millions
Dbv Technologies S a	0.43	$ 12.688 Millions	$ 29.255 Millions
Amgen Inc	0.43	$ 9,301.000 Millions	$ 21,517.000 Millions
Protalix Biotherapeutics inc	0.40	$ 23.399 Millions	$ 57.972 Millions
Champions Oncology Inc	0.39	$ 2.892 Millions	$ 7.483 Millions
Biocardia Inc	0.35	$ 1.421 Millions	$ 4.071 Millions
Agenus Inc	0.35	$ 93.723 Millions	$ 270.666 Millions
Coherus Oncology inc	0.34	$ 159.240 Millions	$ 463.005 Millions
Zeo Scientifix Inc	0.30	$ 1.105 Millions	$ 3.634 Millions
Aptose Biosciences Inc	0.26	$ 3.316 Millions	$ 12.711 Millions
Genetic Technologies Limited	0.24	$ 0.681 Millions	$ 2.801 Millions
Atara Biotherapeutics Inc	0.24	$ 35.292 Millions	$ 148.267 Millions
Kiromic Biopharma Inc	0.24	$ 4.048 Millions	$ 17.057 Millions
Armata Pharmaceuticals Inc	0.21	$ 26.405 Millions	$ 123.181 Millions
Windtree Therapeutics Inc	0.21	$ 1.803 Millions	$ 8.775 Millions
Xtant Medical Holdings Inc	0.20	$ 5.379 Millions	$ 27.450 Millions
Cyclo Therapeutics Inc	0.12	$ 1.122 Millions	$ 9.555 Millions
Tevogen Bio Holdings Inc	0.11	$ 1.135 Millions	$ 10.343 Millions
Calidi Biotherapeutics Inc	0.06	$ 0.836 Millions	$ 13.052 Millions
Tc Biopharm holdings Plc	0.06	$ 0.250 Millions	$ 4.148 Millions

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.